ACTION INTERFERONS AND IFN-INDUCTORS ON TLR/RLRS GENES EXPRESSION AND DIFFERENTIATION OF TUMOR CELL LINES THP-1 AND HCT-116

Objective. To study of known interferons (IFN) type I and IFN-inductors drugs different chemical structure on cell differentiation and expression group of genes of TLR/RLRs, referring to group of pattern-recognition receptors. Materials and methods. Cellular lines ТНР-1 (acute monocytic leukemia) и НСТ-116 (colon adenocarcinoma) were treated by interferons drugs Reaferon, Altevir, Genfakson, Infibeta 10⁵-10⁶ МЕ, IFN-inductors Ridostin 10²-10³ ßg/ml, Cycloferon 625 ßg/ml and Imunomax 2 МЕ during 24 h or 96 h at 37 °С. Gene expression were estimated by method qRT-PCR (CFX-96, Bio-Rad). CD-immuno-phenotypes of ТНР-1 cells were detected by flow cytometric fluorescence method with FITC and PE monoclonal antibodies (FACSCanto II, Becton Dickinson). Results. It was shown that tumor cells THP-1 and HCT-116 have low and variable constitutive levels gene expression of TLR-receptors 2, 3, 4, 7, 8, 9 during passages. This gene status may be connected with incorrect processing of mature mRNA forms. Genes TLR4, TLR8 and factor NFkB are stimulated by interferons and IFN-inductors more high in THP-cells and genes TLR7, TLR8, TLR9 and NFkB - in HCT-cells. Ridostin (mix ssRNA and dsRNA S. cerevisiae) is the best activator of TLR/RLRs receptors. Ridostin increases macrophage marker CD11b, Cycloferon, Imunomax stimulate levels of early T-cell antigen CD7, interferons results in growth of HLA DR. The drugs Cycloferon, Imunomax and Reaferon decrease levels of myeloid suppressor CD38. Conclusion. Group of recombinant IFNs and IFN-inductor drugs various chemical structures regulate TLR/RLRs genes expression differently in THP-1 and HCT-116. TLR/RLRs genes activation are accompanied by CD-phenotypes changes in THP-1 monocytic cell line.

экспрессия генов TLR/RLR, CD-фенотип, препараты ИФН и ИФН-индукторов, клетки ТНР-1, НСТ-116, TLR/RLRs gene expression, CD-phenotype, interferons, IFN-inductors drugs, human tumor cell lines THP-1 and HCT-116

1. Paul-Clark M.J., George P.M., Catheral T. et al. Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol Ther 2012; 135(2): 200-15. DOI: 10.1016/j.pharmthera.2012.05.007. PMID: 22627269.

2. Kawai T., Akira S. Signaling to NF-kappaB by toll-like receptors. Trends Mol Med 2007; 13(11): 460-9. DOI: 10.1016/ j.molmed.2007.09.002. PMID: 18029230.

3. Kutikhin A.G. Association of polymorphisms in TLR genes and in genes of the toll-like receptors signaling pathway with cancer risk. Hum Immunol 2011; 72: 1095-116. DOI: 10.1016/j.humimm.2011.07.307. PMID: 21872627.

4. Pandey S., Singh S., Anang V. et al. Pattern recognition receptors in cancer progression and metastasis. Sanjay Cancer Growth Metastasis 2015; 8: 25-34. DOI: 10.4137/CGM.S24314. PMID: 26279628.

5. Li T.T., Ogino S., Qian Z.R., World J. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. Gastroenterol 2014; 20 (47): 17699-708. DOI: 10.3748/ wjg.v20.i47.17699. PMID: 25548469.

6. Cannova J., Breslin S.J. P., Zhang J. Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases. Front Med 2015; 9 (3): 288-303. DOI: 10.1007/s11684-015-0412-0. PMID: 26297301.

7. Khoo J.J., Forster S., Mansell A. Toll-like receptors as interferon-regulated genes and their role in disease. J Inteferon and Cytokine Res 2011; 31(1): 13-25. DOI: 10.1089/jir.2010.0095. PMID: 21198355.

8. Zitvogel L., Galluzzi L., Kepp O. et al. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15(7): 405-14. DOI: 10.1038/nri3845. PMID: 26027717.

9. Соколова Т.М., Шувалов А.Н., Полосков В.В., Ершов Ф.И. Стимуляция генов сигнальной трансдукции препаратами Ридостин, Циклоферон и Ингавирин. Цитокины и воспаления 2015; 2: 26-34.

10. Ершов Ф.И. Антивирусные препараты. Справочник. 2-е изд. М., 2006.

11. Соколова Т.М., Шувалов А.Н., Шаповал И.М. и др. Активация генов сигнальных путей иммунитета: различная индивидуальная чувствительность клеток крови человека к препаратам интерферонов и индукторов ИФН. Медицинская иммунология 2015; 1: 7-18. DOI: 10.15789/1563-0625-2015-1-7-18.

12. Kaczanowska S., Joseph A.M., Davila E. TLR agonists: our best frenemy in cancer immunotherapy. Cellular & Molecular Immunology 2011; 8: 341-47. DOI: 10.1189/jlb.1012501. PMID: 23475577.

13. Chanput W., Mes J.J., Wichers H.J. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol 2014; 23(1): 37-45. DOI: 10.1016/j.intimp.2014.08.002. PMID: 25130606.

14. Соколова Т.М., Кособокова Е.Н., Шувалов А.Н. и др. Активность генов системы интерферона в клетках аденокарциномы толстого кишечника НСТ-116: регуляция рекомбинантными интерферонами альфа-2 из бактериальных и растительных продуцентов. Российский биотерапевтический журнал 2013; 3: 39-44.

15. Nguyen-Pham T-N., Lim M-S., Nguyen T.A. et al. Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. Cell Mol Immunol 2011; 8(4): 341-7. DOI: 10.1038/cmi. 2011.7. PMID: 21423200.